Mdimune

Mdimune, Inc. is a South Korean biotechnology company established in 2015 by CEO Shingyu Bae. The company is focused on developing a novel drug delivery system (DDS) named the BioDrone® platform. This technology utilizes cell-derived vesicles (CDVs), which are nanoscale vesicles obtained from various human cells through a proprietary extrusion process. The BioDrone® platform is designed to overcome the limitations of conventional cell therapies and enable highly target-specific delivery of various drug payloads, such as small molecules, nucleic acids, and proteins.

The core of Mdimune's business is its BioDrone® platform, which offers a significant advantage in production scalability compared to naturally secreted exosomes, yielding 10 to 30 times more vesicles. This efficiency addresses a key bottleneck in the commercialization of vesicle-based therapeutics. The company's business model revolves around research and development collaborations, co-development, and licensing agreements with pharmaceutical and biotech companies. These partnerships aim to apply the BioDrone® technology to a wide range of unmet medical needs, with a focus on cancer, chronic obstructive pulmonary disease (COPD), osteoarthritis, and other rare diseases. The standard agreement structure includes upfront payments, developmental, regulatory, and sales milestones, as well as royalties.

Mdimune's research pipelines include developing anticancer drugs by loading chemotherapeutics into CDVs and exploring the regenerative potential of stem cell-derived vesicles. The company has engaged in numerous collaborations to advance its technology, including partnerships with Lonza, Johnson & Johnson Innovation (via residency at JLABS @ Shanghai), Reyon Pharmaceuticals for mRNA delivery, and Hanyang University for research on intracellular mechanisms. Mdimune has raised at least $8.82 million in funding from investors including Startup Creasphere, Behigh Investment, and STIC Ventures. The company's BioDrone® technology is protected by patents in the United States, Europe, China, Japan, and Korea.

Keywords: cell-derived vesicles, drug delivery system, BioDrone platform, targeted therapeutics, biopharmaceutical, oncology, rare diseases, nanovesicles, gene therapy, biologics, regenerative medicine, COPD, mRNA delivery, extracellular vesicles, drug development, biotech partnerships, CDVs, platform technology, preclinical studies, anticancer drugs